(NASDAQ: RXST) – RxSight, Inc., an ophthalmic
medical device company dedicated to providing high-quality
customized vision to patients following cataract surgery, today
announced that its Light Adjustable Lens™ system will be the
subject of multiple surgeon presentations at the annual meeting of
the American Society of Cataract and Refractive Surgery (ASCRS)
being held at the San Diego Convention Center on May 5-8,
2023.
Key papers and presentations include:
Friday, May 5LAL for Patients Who
Desire Presbyopia Correction Neda Shamie, MD, ABO (1:10
p.m., SDCC, Upper Level, Room 6A)
Saturday, May 6 Integrating Small
Aperture Technology and Light Adjustable Lenses to Broaden the
Patients Able to Attain Decreased Spectacle Dependence
Cathleen M. McCabe, MD (3:35 p.m., Upper Level, Room 20D)
LAL Customized Monovision Will Minimize the
Disparity Nicole R. Fram, MD, ABO (4:23 p.m., SDCC, Upper
Level, Room 20D)
Sunday, May 7 Refractive Outcomes of
Patients with Corneal Astigmatism after Implantation with a Light
Adjustable Lens, Toric Lens, or Monofocal Lens Francesca
Kahale, MD; Wassef Chanbour, MD; Jason E. Brenner, MD; Samir A.
Melki, MD, PhD (9:20 a.m., SDCC, Upper Level, Room 1B)
A Retrospective Single-Practice, Single-Surgeon,
Multi-Provider Study on the Performance of the Second-Generation
Light Adjustable Lens Avery Zhou, BA, MA; Eva I. Liang,
MD, FASC, ABO (1 :35 p.m., SDCC, Upper Level, Room 3)
Light Adjustable Intraocular Lens and the Effects of
Postoperative Astigmatism on Near Vision Cory J. Pickett,
MSN, FNP-C, COA, CRNO; Sloan W. Rush, MD, ABO; Jason C. Smith, PA
(1:40 p.m., SDCC, Upper Level, Room 3)
Increased Depth of Focus with the Light Adjustable
Intraocular Lens Cory J. Pickett, MSN, FNP-C, COA, CRNO;
Sloan W. Rush, MD, ABO; Jason C. Smith, PA (1:45 p.m., SDCC, Upper
Level, Room 3)
Refractive and Visual Outcomes in Light Adjustable Lens
Surgery Using Fully Automated Manifest Refraction Andrea
Rivas, MD; Erik A. Navas Villar, MD; Nora E. Robledo, OD; Arturo S.
Chayet, MD; Maximiliano Barrera-Sanchez, MD; Ivone Curiel Arce, MD;
Arie Maya, MD, MHA (1:57 p.m., SDCC, Upper Level, Room 3)
Clinical Outcomes of a Light Adjustable Lens in Eyes
with Prior Corneal Refractive Surgery Adam Bleeker, MD;
Marlee E. Jones, BSc; Tanner J. Ferguson, MD; Daniel Terveen, MD;
John P. Berdahl, MD; Brent A. Kramer, MD; Vance M. Thompson, MD
(2:29 p.m., SDCC, Upper Level, Room 3)
Multi-Center Study: Visual Outcomes in 143 Patients
Bilaterally Implanted with the Post-Op Customizable Light
Adjustable Lens (LAL) John A. Vukich, MD (4:40 p.m., SDCC,
Upper Level, Room 1B)
Optimizing Vision at All Distances with the Light
Adjustable Lens (LAL) T. Hunter Newsom, MD, ABO; Brian
Szabo, DO (4:45 p.m., SDCC, Upper Level, Room 1B)
In addition, numerous surgeons will present their LAL experience
at the RxSight booth in the convention exhibit hall (Booth #1911).
A schedule of these presentations, which are not affiliated with
the official ASCRS program, is available at
https://rxsightlal.com/wp-content/uploads/2023/03/RxS-ASCRS-Speaker-Schedule.pdf
and at the company’s booth throughout ASCRS.
About RxSight, Inc.RxSight, Inc. is a
commercial-stage medical technology company dedicated to improving
the vision of patients following cataract surgery. The RxSight®
Light Adjustable Lens system, comprised of the RxSight Light
Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and
accessories, is the first and only commercially available
intraocular lens (IOL) technology that can be adjusted after
surgery enabling doctors to customize and deliver high-quality of
vision to patients after cataract surgery. Additional information
about RxSight can be found at www.rxsight.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. Such statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of activity,
performance or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed, implied or inferred by these forward-looking statements,
and among other things, our ability to maintain cash balances and
successfully commercialize or partner our product candidates
currently under development. Potential risks and uncertainties may
also include the continued efficacy and safety profile of our
products as might be suggested in presentations at the ASCRS
meeting. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "could," "would,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," or "continue" or
the negative of such terms and other same terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. We undertake no obligation to update any of the
forward-looking statements after the date of this press release to
conform those statements to reflect the occurrence of unanticipated
events, except as required by applicable law.
Company Contact:Shelley B. ThunenChief
Financial Officersthunen@rxsight.com
Investor Relations Contact:ir@rxsight.com
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jun 2024 to Jul 2024
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jul 2023 to Jul 2024